Please sign in so that we can notify you about a reply
Indications/Uses
Management of HTN, angina & heart failure.
Dosage/Direction for Use
Individualized dosage. Essential HTN 5 mg once daily. Diastolic BP up to 105 mmHg 2.5 mg once daily. May be increased up to 10 mg once daily if required. Max: 20 mg once daily. CHD (angina pectoris) 5 mg once daily. May be increased to 10 mg once daily. Max: 20 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Acute heart failure, cardiogenic shock, 2nd- or 3rd-degree AV block (w/o pacemaker), sick sinus syndrome, SA block; symptomatic bradycardia or hypotension; severe bronchial asthma or COPD, severe forms of peripheral arterial occlusive disease or Raynaud's syndrome, untreated pheochromocytoma & metabolic acidosis.
Special Precautions
Patients w/ ischemic heart disease, HTN, angina pectoris & accompanying heart failure; DM, 1st-degree AV block, Prinzmetal's angina, peripheral arterial occlusive disease, ongoing desensitization therapy & those on strict fasting; existing or history of psoriasis, pheochromocytoma & those undergoing general anesth. Avoid abrupt w/drawal. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn.
Adverse Reactions
Bradycardia; worsening of preexisting heart failure, dizziness, headache; GI complaints eg, nausea, vomiting, diarrhea, constipation; feeling coldness or numbness in extremities, hypotension & asthenia.
Drug Interactions
Potentiated AV conduction time & increased -ve inotropic effect w/ class I & III antiarrhythmic drugs (eg, quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone, amiodarone). Increased AV conduction time w/ parasympathomimetics & digitalis glycosides. Increased risk of hypotension w/ Ca channel blockers, anesth, MAOIs & other drugs w/ BP-lowering potential (eg, TCAs, barbiturates, phenothiazide). Potential systemic effect w/ topical β-blockers. Increased blood sugar-lowering effect w/ insulin & oral antidiabetic drugs. Reduced hypotensive effect w/ NSAIDs. May reduce effect w/ β-sympathomimetics (eg, isoprenaline, dobutamine). Increased risk of bradycardia w/ mefloquine. Risk of hypertensive crisis w/ MAOIs. Reduced t½ w/ rifampicin. Exacerbation of peripheral circulatory disturbance w/ ergotamine derivatives.
MedsGo Class
Beta-Blockers
Features
Dosage
5mg
Ingredients
- Bisoprolol Fumarate
Packaging
Film-Coated Tablet 1's
Generic Name
Bisoprolol Fumarate
Registration Number
DRP-2514-01
Classification
Prescription Drug (RX)
Product Questions
Questions
